linjc16/ctgov huggingface dataset:
Observational Study on Respiratory Impact of High-frequency Jet Ventilation (JVHF) in Interventional Radiology (RI)

Study Overview
=================
Brief Summary
-----------------
Jet ventilation is used in interventional radiology to reduce respiratory movement and facilitate tumor destruction. The purpose of this study is to describe the respiratory impact of this technique

Detailed Description
-----------------
Use imaging and respiratory data to describe the impact of JVHF during tumor thermoablation procedures

Official Title
-----------------
Observational Study on Respiratory Impact of High-frequency Jet Ventilation (JVHF) in Interventional Radiology (RI)

Conditions
-----------------
Anesthesia Complication

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major patient Patient benefiting from an abdominal tumor thermoablation procedures Patient who gave consent Patient with a social protection scheme Exclusion Criteria: Pulmonary thermoablation procedures Thermoablation of abdominal tumors required a transpleural passage Patient under guardianship or curatorship Patient not understanding French

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluate the respiratory impact after the use of JVHF after thermoablation of a solid abdominal tumour. | Respiratory complication rate. | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Describe the number of ventilatory disorders | Score Radiological Atelectasis Score (RAS) of Richter Larsen - RAS: 0, clear lung field; 1, plate like atelectasis or slight infiltration; 2, partial atelectasis; 3, lobar atelectasis; 4, bilateral lobar atelectasis. | through study completion, an average of 1 year | 
| Describe the incidence of hypoxemia during JVHF | Difference between oxygen saturation at the end of the procedure and at the beginning of the procedure | through study completion, an average of 1 year | 
| Describe the incidence of hypercapnia at the time of a JVHF | Difference between end of procedure and beginning of procedure capnia | through study completion, an average of 1 year | 
| Describe the incidence of barotraumatic pulmonary lesions at the time of a JVHF | Presence of barotraumatic pulmonary lesions on the imaging | through study completion, an average of 1 year |
Corneal Specular Microscopy in Infectious and Noninfectious Uveitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether some endothelium morphologic variables are different between infectious and noninfectious uveitis group using a noncontact specular microscopy device.

Conditions
-----------------
Uveitis

Intervention / Treatment
-----------------
* Device: noncontact specular microscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with infectious and noninfectious uveitis in any activity level and presence of keratic precipitates. Exclusion Criteria: Patients with previous ocular surgery, trauma, contact lens history, corneal dystrophy, corneal edema and high intraocular pressure Any other anterior segment disorders affecting the corneal endothelium.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: noncontact specular microscopy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Keratic precipitates
Microarray Analysis of microRNA Expression in Basal Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
Perturbations in microRNA (miRNA) expression profiles has been reported for a variety of cancers. This study will be an exploratory analysis of miRNA expression in basal cell carcinoma by miRNA expression profiling using microarrays.

Detailed Description
-----------------
Perturbations in the expression profiles of microRNAs (miRNAs) have been reported for a variety of different cancers. Basal cell carcinoma (BCC) of the skin has not been systematically evaluated regarding differentially expressed miRNAs. Patients with BCC are included in the study to perform an exploratory analysis by miRNA expression profiling using microarrays. Expression levels of miRNA candidates will be validated by TaqMan real-time quantitative polymerase chain reaction (RT-PCR).

Official Title
-----------------
Microarray Analysis of microRNA Expression in Basal Cell Carcinoma

Conditions
-----------------
Basal Cell Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Basal Cell Carcinoma Exclusion Criteria: Other Skin Cancer than Basal Cell Carcinoma

Ages Eligible for Study
-----------------
Minimum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| basal cell carcinoma<br> | |
| non-lesional skin<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Pulmonary Embolism Short-term Clinical Outcomes Registry

Study Overview
=================
Brief Summary
-----------------
The overall goal of this clinical research study is to prospectively assess primary outcomes related to pulmonary embolism (PE) that occur immediately (within 5 days) and within 30 days. The secondary goal is to compare validated prediction models and a modified European Society of Cardiology (ESC) approach that is primarily right ventricle dysfunction (RVD) driven with clinical risk assessment being secondary, and with primary outcomes of clinical deterioration within 5 days.

Detailed Description
-----------------
The investigators wish to develop the Pulmonary Embolism Short-term Clinical Outcomes Registry (PE-SCOR). The investigators also wish to determine the incidence of death and circulatory and respiratory deterioration, and administration of reperfusion therapy within 5 days in PE patients. The study will also evaluate the sensitivity, specificity and positive and negative predictive values of each RVD assessment option. The investigators will also derive a prediction model for PE patients for the primary outcome within five days. Finally, investigators will determine the functional outcomes of PE patients 30 days after PE.

Official Title
-----------------
Pulmonary Embolism Short-term Clinical Outcomes Registry (PE-SCOR)

Conditions
-----------------
Pulmonary Embolism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 18 years or older with image confirmed acute pulmonary embolism diagnosed within 12 hours of ED presentation will be eligible for enrollment. Exclusion Criteria: Patients who refuse consent for 30-day clinical contact and follow-up.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Deterioration | Presence of any one clinical deterioration variable: death, circulatory or respiratory dysfunction, reperfusion interventions. | 5 days | 
| Right ventricular dysfunction (RVD) | Presence of any one indicator of RVD: any one goal directed echocardiography finding of RVD (right ventricle (RV) enlargement or, leftward deviation of the interventricular septum, or RV systolic dysfunction by longitudinal movement of the tricuspid annulus of the RV free wall), CT right ventricle : left ventricle ratio greater or equal to 1, positive troponin or B-type Natriuretic Peptide, EKG injury and ischemia patterns of RVD | Index visit | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional Outcome | Pulmonary Embolism Quality of Life (PEmb-QoL) questionnaire | 30 days | 
| Pulmonary Embolism Complications | Presence of any one variable: recurrence of pulmonary embolism, subsequent hospitalizations, major and minor bleeding | 30 days |
Children's Sleep in the ICU

Study Overview
=================
Brief Summary
-----------------
Prospective evaluation of sleep in children admitted to the Intensive Care Unit at Nationwide Children's Hospital to determine how children sleep while admitted to the Intensive Care Unit

Conditions
-----------------
Children Admitted to the Intensive Care Unit

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient admitted to the Intensive Care Unit, or soon to be admitted to the ICU Age from 0 days to 17 years 364 days at the time of enrollment Any patient with anticipated ICU stay of at least overnight with a minimum of 12 hours duration Exclusion Criteria: Any patient with Admitted with Traumatic Brain Injury, Admitted with an Active Seizure Disorder, Severe Developmental Delay that might impair normal sleep architecture, Known abnormal EEG, any patient actively receiving Mechanical Ventilation

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total Sleep Time |  | 24 Hours |
Clinical Outcome of Pediatric Dermatofibrosarcoma Protuberans

Study Overview
=================
Brief Summary
-----------------
Retrospective review of clinical outcome of pediatric Dermatofibrosarcoma Protuberans (PDFSP) after active invitation

Detailed Description
-----------------
Soft tissue sarcoma was rarely seen in pediatric patients, and pediatric Dermatofibrosarcoma Protuberans (PDFSP) was even rare. To our knowledge, the largest report constituted of 19 cases (five of them had no follow-up (FU) status) (1). So we proposed this retrospective study based on the cancer registry of our hospital. Twelve cases who were diagnosed as DFSP before age of 18 were identified. But all of them had been lost of FU for at least two years. So we will try to contact these patients and asked them to be back to our clinic for routine surveillance (history taking and physical exam and optional local image/chest xray) and quality of life (QoL) evaluation after pathological review if this clinical study was approved (2)

Official Title
-----------------
Retrospective Clinical Outcome Study of Pediatric Dermatofibrosarcoma Protuberans: Single Institutional Experience of Twelve Cases From 1977-2002

Conditions
-----------------
Soft Tissue Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed as DFSP before age of 18 after pathological review according to the cancer registry of our hospital Exclusion Criteria: age > 18 at diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pediatric Dermatofibrosarcoma Protuberans
High Dose Candesartan Versus Quinapril for Restenosis Prophylaxis After Stent Angioplasty

Study Overview
=================
Brief Summary
-----------------
The study is designed to test the hypothesis that high dose candesartan treatment compared to quinapril is able to reduce intima hyperproliferation and the restenosis rate after stent angioplasty in peripheral occlusive artery disease.

Detailed Description
-----------------
Patients are randomly assigned to treatment with either candesartan 32 mg/d or Quinapril 20 mg/d before the angioplasty. Walking distance, intima media thickness and crurobrachial pressure ratios are compared after 6 weeks, 3 months and 6 months. After 6 months an angiographic control is performed.

Conditions
-----------------
Arterial Occlusive Diseases

Intervention / Treatment
-----------------
* Drug: candesartan (drug) or quinapril (drug)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male and female peripheral occlusive arterial disease Stad IIb Fontaine classification Exclusion Criteria: patients with lesions not available for PTA renal insufficiency patients on calcium-antagonists

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: candesartan (drug) or quinapril (drug)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Restenosis/reintervention after 6 months |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain-free walking distance |  |  | 
| crurobrachial pressure ratios |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
restenosis, intima hyperproliferation, stent angioplasty, pain-free walking distance
The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma

Study Overview
=================
Brief Summary
-----------------
A retrospective analysis will be performed regarding the usefulness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with aggressive non Hodgkin Lymphoma.

Detailed Description
-----------------
Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT as a predictive value for progression free survival and overall survival is evaluated

Official Title
-----------------
Evaluation of the Prognostic Value of Early Interim PET/CT for Prediction of Progression Free Survival of Patients With Aggressive B Cells Non Hodgkin Lymphoma

Conditions
-----------------
Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aggressive non-Hodgkin lymphoma b cells age 18-70 bilirubin less then 2 creatinine less then 2 Pet/CT performed post 2 cycles Exclusion Criteria: no PET/CT post 2 cycles performed bilirubin >2 creatinine more then 2 HIV positivity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PET/CT<br>all patients with aggressive lymphoma who had a baseline and interim pet/ct study | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression free survival |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PET/CT, Aggressive non-Hodgkin Lymphoma
Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving Antiplatelet Therapy With Clopidogrel (Plavix)

Study Overview
=================
Brief Summary
-----------------
Clopidogrel (Plavix), a platelet ADP receptor antagonist, has become the standard of care to prevent thrombosis in interventional cardiology and is increasingly being used in unstable angina and NSTEMI. An increasing number of patients are referred to emergent or urgent CABG, and several studies, as well as our own experience, have shown that preoperative administration of irreversible platelets inhibitors increase the risk of bleeding complications following CABG.

Detailed Description
-----------------
Aprotinine (Trasylol) is a potent antifibrinolytic agent known to reduce bleeding after cardiac surgery. The most commeon practice is to give Trasylol in high doses immediately before surgery, during the operation, and during the first postoperative hours. However, it has also been shown that there is a hemostatic effect of the drug when given in a lower dose postoperatively, but this remains unclear.

Official Title
-----------------
Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Procedure: Aprotinine


Participation Criteria
=================
Eligibility Criteria
-----------------
All coronary bypass operations in patients receiving Plavix within the last 7 days
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Aprotinine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perioperative bleeding |  |  | 
| Blood transfusions |  |  | 
| Reoperation |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in costs related to low/high dose |  |  |
Effect of Intranasal Vasopressin on Cooperative Behavior in Schizophrenia

Study Overview
=================
Brief Summary
-----------------
The study investigates the effect of 40IU of intranasal vasopressin on cooperative behavior in patients with schizophrenia

Official Title
-----------------
Effect of Intranasal Vasopressin on Cooperative Behavior in Schizophrenia

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: Vasopressins
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-45 years Diagnosed as Schizophrenia or Schizophreniform disorder as per DSM IV TR At least 7 years of formal education MOCA score >24 Exclusion Criteria: Diagnoses of SIADH, Diabetes Insipidus Substance dependence in the past 12 months, excluding nicotine dependence Current comorbid axis 1 psychiatric disorder Hypersensitivity or previous allergy to Vasopressin Serious medical or neurological illness which may interfere with assessment and administration of vasopressin Hypertension Impaired renal functions based on serum creatinine above 1.5 Electrolyte imbalance Receiving ECT or has received ECT in the past 8 weeks Clinical history of mental retardation Pregnancy • Lactation Risk of harm to self or others Any significant nasal pathology which may hinder the intranasal absorption of the drug Hearing or visual impairment that significantly affects the comprehension and execution of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Interventional Model Description: After completion of clinical assessments all subjects will receive either 40 IU of vasopressin or saline in counterbalanced order on two separate days and perform the behavioral tasks
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: vasopressin<br>All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design | Drug: Vasopressins<br>* 40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced<br>|
| Placebo Comparator: Placebo<br>All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design | Drug: Placebo<br>* 40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Performance in Dictator game | Amount of money shared in dictator game | 60 minutes | 
| Performance in stag hunt game | Security level in stag hunt game | 60 minutes |